ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 724

Survival, Hospitalization or Need for Combination Therapy At One Year in Patients with Scleroderma-Associated Pulmonary Arterial Hypertension

Robyn T. Domsic1, Lorinda Chung2, Jessica K. Gordon3, Yona Cloonan4, Virginia D. Steen5 and PHAROS Investigators6, 1Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, 3Rheumatology, Hospital for Special Surgery, New York, NY, 4Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, 5Department of Rheumatology, Georgetown University Medical Center, Washington, DC, 6Washington, DC, DC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: morbidity and mortality, pulmonary complications and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of death in patients with systemic sclerosis (SSc).  Although survival has improved with PAH-specific medications in the last decade, the optimal therapy remains unknown.  We sought to compare the one year outcome of SSc-PAH patients with different therapeutic classes of PAH-specific medications. 

Methods:

Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) is a multi-center prospective registry of SSc patients at high risk for PAH or with definite PH diagnosed by right heart catheterization (RHC) within 6 months of enrollment.  To be included in this analysis, patients had to have World Health Organization (WHO) Group I PAH, and have received a PAH-specific medication for > 3 months duration.   We assessed patient outcomes for four therapeutic classes: endothelin receptor antagonists (ERA), phosphdiesterase type 5 inhibitors (PDE-5), prostacyclins (PCA) and those started immediately on combination therapy (≥2 of the other classes).  A Kaplan-Meier curve was estimated for 1 year survival from the time the PAH treatment was started, and differences between the drug classes were assessed by the log-rank test.   Rates of hospitalizations at one year were compared by chi-square tests.   

Results: In the PHAROS registry 160 individuals have PAH, of whom 120 either had≥ 1 year of follow-up or had died prior to 1year of follow-up.  Of these, 101 had been treated with a PAH medication for > 3 months and comprised the analysis population.  The mean age was 59.0 ± 10.4 years, 85% were female, 80% Caucasian and 11% African-American.  67% were classified as limited cutaneous SSc.  Overall, initial therapy was a PDE-5 in 47%, ERA in 30%, PCA in 13% and combination therapy in 10%.  In the PCA group 85% started inhaled, and 15% started parental therapy.   With those with a baseline NYHA class within two months of therapy initiation, 25% of the PCA group were class IV, as compared to 20% in the combination, 0% ERA and 7% PDE5.   At one year 7% (n=7) on medications had died, whereas 10% had died at one year in the entire PHAROS cohort.  There was a statistically significant difference between the drug classes with 98% of PDE-5, 97% of ERA, 69% of PCA and 90% of combination therapy alive at one year (p=0.002).   At one year 28% of patients had been hospitalized, but there was no difference in rate of all-cause hospitalization (p=0.78) or PAH-related hospitalizations (p=0.91) between the drug classes.   Similarly, there was no difference in progression to combination therapy with 27% of PDE5, 23% of ERA and 13% of PCA (p=0.67).   

Conclusion: At one year there is no difference in rates of hospitalization or progression to combination drug therapy among the PAH-specific drug classes.  However, there was a difference in one-year survival between the drug classes, with those started on PCAs clearly having the lowest survival.   This may reflect that those patients had more severe pulmonary vascular disease at baseline.  Further follow-up is needed to determine whether long-term outcomes differ between the PAH therapeutic drug classes.


Disclosure:

R. T. Domsic,
None;

L. Chung,

Gilead and Actelion,

5,

Gilead, Actelion, Pfizer, United Therapeutics,

2;

J. K. Gordon,
None;

Y. Cloonan,
None;

V. D. Steen,

Gilead,

5;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survival-hospitalization-or-need-for-combination-therapy-at-one-year-in-patients-with-scleroderma-associated-pulmonary-arterial-hypertension/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology